

CARDIOLOGY ENROLLMENT FORM



DATE: _____ SHIP TO:
 DATE NEEDED: _____ PATIENT OFFICE

PATIENT INFO
 NAME _____ E-MAIL _____ Spanish Speaking: Yes No DOB _____ MALE FEMALE
 ADDRESS _____ CITY _____ STATE _____ ZIP _____
 HOME TELEPHONE _____ MOBILE PHONE _____ SS# _____

PLEASE FAX COPY OF INSURANCE CARD (FRONT & BACK) also FAX clinical notes, labs, and test with this referral form

DIAGNOSIS CODE Date of Diagnosis: _____ E78.01 Familial Hypercholesterolemia: homozygous heterozygous
 E78.0 Pure hypercholesterolemia - Check one of the following sub-diagnoses: ASCVD (Please indicate history/risk factors) _____
 LDL not controlled despite max-tolerated statin dose
 Statin-intolerant (list reason) _____ Other: _____

CLINICAL INFORMATION

<p>Past Medical History: Please indicate if the patient has experienced any of the following events:</p> <input type="checkbox"/> Myocardial infarction <input type="checkbox"/> Unstable Angina requiring hospitalization <input type="checkbox"/> Heart failure requiring hospitalization <input type="checkbox"/> Coronary revascularization <input type="checkbox"/> Stroke <input type="checkbox"/> TIA	<p>Patient Risk Factors: Please indicate if the patient has any risk factors:</p> <input type="checkbox"/> Hypertension <input type="checkbox"/> Diabetes Mellitus <input type="checkbox"/> Metabolic syndrome <input type="checkbox"/> Current smoker <input type="checkbox"/> Family history of premature CAD <input type="checkbox"/> Known familial hypercholesterolemia	<p>Height: _____ inches Weight: _____ <input type="checkbox"/> kg <input type="checkbox"/> lb Allergies? <input type="checkbox"/> Latex <input type="checkbox"/> Other: _____ <input type="checkbox"/> NKDA LABS: LDL: _____ HDL: _____ Triglycerides: _____ Lipoprotein a: _____ Total Cholesterol: _____ Date of Labs: _____ Concomitant Meds: _____</p>
---	---	---

PRIOR FAILED MEDICATIONS:

<input type="checkbox"/> Crestor® (rosuvastatin) Length of Treatment _____ to _____ Reason for Discontinuing _____	<input type="checkbox"/> Lipitor® (atorvastatin) Length of Treatment _____ to _____ Reason for Discontinuing _____	<input type="checkbox"/> Zetia® (ezetimibe) Length of Treatment _____ to _____ Reason for Discontinuing _____	<input type="checkbox"/> Zocor® (simvastatin) Length of Treatment _____ to _____ Reason for Discontinuing _____
Medication _____ Length of Treatment _____ to _____ Reason for Discontinuing _____	Medication _____ Length of Treatment _____ to _____ Reason for Discontinuing _____		

PCSK9 INHIBITORS				
DRUG NAME	DOSAGE FORM / STRENGTH	DIRECTIONS	QUANTITY	REFILLS
<input type="checkbox"/> Praluent™ (alirocumab)	<input type="checkbox"/> 75mg/ml Prefilled PEN <input type="checkbox"/> 75mg/ml Prefilled SYRINGE <input type="checkbox"/> 150mg/ml Prefilled PEN <input type="checkbox"/> 150mg/ml Prefilled SYRINGE	<input type="checkbox"/> Inject 1 pen/PFS SC every other week. <input type="checkbox"/> Inject 300mg (150mg x2 pens/syringes) SC every 4 weeks <input type="checkbox"/> Other: _____	<input type="checkbox"/> 2 pens / syringes <input type="checkbox"/> 11 <input type="checkbox"/> Other: _____	
<input type="checkbox"/> Repatha® (evolocumab)	<input type="checkbox"/> 140mg/ml Autoinjector PEN <input type="checkbox"/> 140mg/ml Prefilled SYRINGE	<input type="checkbox"/> Inject 140mg (1 pen/PFS) SC every other week. <input type="checkbox"/> Inject 420mg (3 pens/PFS) SC once a month. <input type="checkbox"/> Other: _____	<input type="checkbox"/> 2 pens / syringes <input type="checkbox"/> 11 <input type="checkbox"/> 3 pens / syringes <input type="checkbox"/> Other: _____	
<input type="checkbox"/> Repatha® Pushtronex™	<input type="checkbox"/> 420mg/3.5ml Pushtronex™	<input type="checkbox"/> Administer 420 mg subcutaneously via on-body infusor over 9 minutes every 4 weeks <input type="checkbox"/> Other: _____	<input type="checkbox"/> 1 x 420 / 3.5ml Pushtronex™ <input type="checkbox"/> Other: _____	<input type="checkbox"/> 11

OTHER MEDICATIONS				
DRUG NAME	DOSAGE FORM / STRENGTH	DIRECTIONS	QUANTITY	REFILLS
Crestor® (rosuvastatin)				
Lipitor® (atorvastatin)				
Zetia® (ezetimibe)				
Zocor® (simvastatin)				

INJECTION TRAINING Patient has received injection training Physician Office to provide injection training Pharmacy to provide injection training

PRESCRIBER INFORMATION

Prescriber's Name: _____ Contact Person: _____
 Telephone: _____ Fax: _____ Email: _____
 Office Address: _____ City: _____ State: _____ Zip: _____
 NPI # : _____ DEA # : _____ TAX ID # : _____ Medicaid Provider # : _____

*

PRESCRIBER'S SIGNATURE _____ (DATE) _____ *IF BRAND DRUGS ARE PREFERRED, HANDWRITE "BRAND MEDICALLY NECESSARY" ABOVE

I authorize the Pharmacy noted above and its representatives to act as an agent to initiate and execute the insurance prior authorization process. ©ReCept, LP All rights Reserved

IMPORTANT NOTICE: This facsimile transmission is intended to be delivered only to the named addressee and may contain material that is confidential, privileged, proprietary or exempt from disclosure under applicable law. If it is received by anyone other than the named addressee, the recipient should immediately notify the sender at the address and telephone number set forth herein and obtain instructions as to disposal of the transmitted material. In no event should such material be read or retained by anyone other than the named addressee, except by express authority of the sender to the named addressee. © REF--Cardiology-E- 5174-05-02-2018